Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 13 April 2015 | By Michael Mezher
A European committee has confirmed that high doses of ibuprofen, a popular over-the-counter (OTC) anti-inflammatory drug, can increase a patient's risk for cardiovascular issues.
Ibuprofen belongs to a class of drugs, called non-steroidal anti-inflammatory drugs (NSAIDs), which includes drugs such as diclofenac, naproxen and aspirin. NSAIDs already have a warning about increased risk of blood clots included in the information distributed with such products in the EU. The warning recommends that NSAIDs should "be used at the lowest effective dose and for the shortest period of time necessary," to reduce cardiovascular risks.
The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has said that patients taking ibuprofen at doses of 2,400 mg or more per day are at a higher risk of heart attack or stroke than those taking lower doses. Healthcare providers are advised to weigh the risks of prescribing doses of 2,400 mg or greater, and take into consideration a patient's cardiovascular history and other risk factors. To ensure safe prescribing, PRAC is recommending the European Commission (EC) update the product information for products containing ibuprofen to reflect the greater risk associated with high doses.
The committee also clarified that the level of risk does not increase when taking up to 1,200 mg of ibuprofen, which is typically the highest recommended dose for OTC versions. OTC ibuprofen products usually advise taking up to 200–400 mg, 3-4 times daily; however, patients are sometimes prescribed 800 mg formulations of the drug.
The review also looked at possible interactions between ibuprofen and low-dose aspirin, which often is prescribed to reduce clotting. The reviewers noted that some studies found ibuprofen to reduce the anti-clotting properties of aspirin, but did not have enough data to determine the effect of the long-term simultaneous use of both drugs. PRAC recommends that product information for ibuprofen should also be updated to include information about possible interactions between ibuprofen and aspirin.
Now that PRAC has completed its review, the recommendations will move to the Coordination Group for Mutual Recognition and Decentralised Procedures—Human (CMDh). If CMDh adopts the recommendations, they will automatically take effect in Member States where ibuprofen is authorized, and be brought to the EC to consider for EU-wide adoption.
EMA Press Release
Tags: Ibuprofen, NSAIDs, PRAC, Pharmacovigilance Risk Assessment Committee
Regulatory Focus newsletters
All the biggest regulatory news and happenings.